申请人:Pfizer Inc.
公开号:US04835165A1
公开(公告)日:1989-05-30
A cardiac antiarrhythmic agent of the formula: ##STR1## or a pharmaceutically acceptable salt thereof; wherein R is R.sup.3 SO.sub.2 NH--, R.sup.3 CONH-- or R.sup.1 R.sup.2 NSO.sub.2 --; R.sup.1 and R.sup.2 are each independently H or C.sub.1 -C.sub.4 alkyl; R.sup.3 is C.sub.1 -C.sub.4 alkyl, C.sub.3 -C.sub.7 cycloalkyl or --NR.sup.1 R.sup.2 where R.sup.1 and R.sup.2 are as defined above; and Het is either (a) a 2-, 3- or 4-pyridyl group optionally substituted by a C.sub.1 -C.sub.4 alkyl or an amino group, or (b) a 2-imidazolyl group optionally substituted by one or two C.sub.1 -C.sub.4 alkyl groups.
一种心脏抗心律失常药物的化学式为:##STR1## 或其药用可接受盐;其中R为R.sup.3 SO.sub.2 NH--,R.sup.3 CONH--或R.sup.1 R.sup.2 NSO.sub.2 --;R.sup.1和R.sup.2分别独立地是H或C.sub.1 -C.sub.4烷基;R.sup.3是C.sub.1 -C.sub.4烷基,C.sub.3 -C.sub.7环烷基或--NR.sup.1 R.sup.2,其中R.sup.1和R.sup.2如上定义;Het是(a)一个2-,3-或4-吡啶基,可选择地被C.sub.1 -C.sub.4烷基或氨基取代,或(b)一个2-咪唑基,可选择地被一个或两个C.sub.1 -C.sub.4烷基取代。